Pacira BioSciences (NASDAQ:PCRX) Stock Rating Cut to “Strong Sell” at Zacks Research

Zacks Research lowered shares of Pacira BioSciences (NASDAQ:PCRX) from a hold rating to a strong sell rating in a report published on Monday morning,Zacks reports.

A number of other equities analysts have also weighed in on the stock. Weiss Ratings lowered shares of Pacira BioSciences from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, September 16th. HC Wainwright reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Pacira BioSciences in a research report on Wednesday, July 1st. Leerink Partners started coverage on Pacira BioSciences in a research note on Wednesday, September 9th. They issued a “market perform” rating and a $28.00 target price for the company. Royal Bank Of Canada upped their target price on Pacira BioSciences from $24.00 to $25.00 and gave the company a “sector perform” rating in a research note on Wednesday, August 5th. Finally, Needham & Company LLC increased their target price on Pacira BioSciences from $32.00 to $33.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $30.14.

Pacira BioSciences Stock Performance

NASDAQ PCRX opened at $24.76 on Monday. The stock has a market capitalization of $986.93 million, a price-to-earnings ratio of 70.74 and a beta of 0.25. The business’s 50 day moving average is $25.20 and its two-hundred day moving average is $24.39. Pacira BioSciences has a 12-month low of $18.80 and a 12-month high of $27.66. The company has a current ratio of 5.04, a quick ratio of 3.94 and a debt-to-equity ratio of 0.54.

Pacira BioSciences (NASDAQ:PCRX) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.65 by $0.08. The business had revenue of $192.40 million during the quarter, compared to analysts’ expectations of $191.06 million. Pacira BioSciences had a return on equity of 9.68% and a net margin of 1.96%.The company’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period last year, the firm earned $0.74 EPS. Research analysts expect that Pacira BioSciences will post 1.91 EPS for the current year.

Insiders Place Their Bets

In other Pacira BioSciences news, insider Jonathan Slonin sold 3,040 shares of Pacira BioSciences stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $23.23, for a total transaction of $70,619.20. Following the sale, the insider directly owned 216,384 shares in the company, valued at $5,026,600.32. The trade was a 1.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Pacira BioSciences

Several institutional investors and hedge funds have recently made changes to their positions in PCRX. Global Retirement Partners LLC acquired a new stake in shares of Pacira BioSciences in the second quarter valued at approximately $51,000. Meeder Asset Management Inc. bought a new position in Pacira BioSciences during the first quarter valued at about $46,000. State of Wyoming acquired a new stake in Pacira BioSciences in the 2nd quarter valued at about $78,000. PNC Financial Services Group Inc. lifted its holdings in Pacira BioSciences by 15.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,751 shares of the company’s stock valued at $85,000 after acquiring an additional 492 shares during the last quarter. Finally, Keating Financial Advisory Services Inc. bought a new position in shares of Pacira BioSciences during the 2nd quarter valued at about $110,000. 99.73% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Pacira BioSciences

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Pacira granted Molteni Farmaceutici exclusive rights to commercialize EXPAREL in the European Union and United Kingdom. The agreement expands access to Pacira’s opioid-sparing postsurgical pain treatment and supports management’s “5×30” growth strategy by extending the product’s international reach. Financial terms were not disclosed. Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL
• Positive Sentiment: Analysts tracked by American Banking News have a consensus price target of $30.14, above the current $24.76 level. That target indicates potential upside if Pacira executes on its commercial expansion and improves earnings growth. Pacira BioSciences Consensus Target Price
• Neutral Sentiment: Coverage of the Molteni transaction highlights an “undervalued” narrative, but investors will likely look for evidence that the European launch generates meaningful revenue and profitability before assigning greater value to the deal. Pacira BioSciences on Its Molteni Deal and the Undervalued Narrative
• Negative Sentiment: Zacks Research downgraded PCRX from “Hold” to “Strong Sell.” The downgrade is the clearest near-term negative catalyst and may raise concerns about valuation, earnings momentum, or execution despite the European partnership. Zacks Research Downgrades Pacira BioSciences to Strong Sell

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain-management products. The company’s portfolio is designed to help manage acute and chronic pain while reducing reliance on traditional opioid therapies.

Its principal product is EXPAREL, an extended-release formulation of bupivacaine used to provide postsurgical pain relief. Pacira also markets ZILRETTA, an extended-release corticosteroid injection for osteoarthritis-related knee pain, and the iovera° system, a handheld cryoanalgesia device intended to temporarily block peripheral nerves and provide targeted pain relief.

Originally known as Pacira Pharmaceuticals, the company adopted the name Pacira BioSciences in 2018 to reflect its broader focus on innovative therapies and technologies.